Blocking fibrotic signaling in fibroblasts from patients with carpal tunnel syndrome
- 3 May 2017
- journal article
- review article
- Published by Wiley in Journal of Cellular Physiology
- Vol. 233 (3) , 2067-2074
Abstract
Fibrosis of the subsynovial connective tissue (SSCT) in carpal tunnel syndrome (CTS) patients is increasingly recognized as an important aspect of CTS pathophysiology. In this study, we evaluated the effect of blocking profibrotic pathways in fibroblasts from the SSCT in CTS patients. Fibroblasts were stimulated with transforming growth factor β1 (TGF‐β1), and then treated either with a specific fibrosis pathway inhibitor targeting TGF‐β receptor type 1 (TβRI), platelet‐derived growth factor receptor (PDGFR), epidermal growth factor receptor (EGFR), or vascular endothelial growth factor receptor (VEGFR). Fibrosis array and quantitative real‐time polymerase chain reaction of fibrotic genes were evaluated. Array gene expression analysis revealed significant down‐regulation of multiple fibrotic genes after treatment with TβRI, PDGFR, and VEGFR inhibitors. No array fibrotic genes were significantly down‐regulated with EGFR inhibition. Further gene expression analysis of known CTS fibrosis markers collagen type I A2 (Col1), collagen type III A1 (Col3), connective tissue growth factor (CTGF), and SERPINE1 showed significantly down‐regulation after TβRI inhibition. In contrast, VEGFR inhibition significantly down‐regulated CTGF and SERPINE1, whereas, PDGFR and EGFR inhibition significantly down‐regulated Col3. Taken together the inhibition of TβRI appears to be the primary mediator of fibrotic gene expression in fibroblasts from CTS patients. TGF‐β/Smad activity was further evaluated, and as expected inhibition of Smad activity was significantly down‐regulated after inhibition of TβRI, but not with PDGFR, VEGFR, or EGFR inhibition. These results indicate that local therapies specifically targeting TGF‐β signaling alone or in combination offer the potential of a novel local antifibrosis therapy for patients with CTS.Keywords
Funding Information
- National Institutes of Health (AR49823, F32 AR063596)
- Mayo Clinic
This publication has 51 references indexed in Scilit:
- Concomitant Targeting of EGF Receptor, TGF-beta and Src Points to a Novel Therapeutic Approach in Pancreatic CancerPLOS ONE, 2012
- Non-Smad pathways in TGF-β signalingCell Research, 2008
- LapatinibNature Reviews Drug Discovery, 2007
- Lapatinib induces apoptosis in trastuzumab-resistant breast cancer cells: effects on insulin-like growth factor I signalingMolecular Cancer Therapeutics, 2007
- VEGF, a prosurvival factor, acts in concert with TGF-β1 to induce endothelial cell apoptosisProceedings of the National Academy of Sciences, 2006
- VEGF receptor signalling ? in control of vascular functionNature Reviews Molecular Cell Biology, 2006
- Transforming growth factor-?-induced stimulation of formation of collagen fiber network and anti-fibrotic effect of taurine in an in vitro model of hepatic fibrosisHepatology Research, 2004
- The biology of VEGF and its receptorsNature Medicine, 2003
- Biochemical evaluation of serum and flexor tenosynovium in carpal tunnel syndromeMicrosurgery, 2002
- Transforming Growth Factor-β (TGF-β) Stimulates the Expression of β1 Integrins and Adhesion by Rat Mesangial CellsExperimental Cell Research, 1996